On October 11, 2016, EpimAb and Kymab, a leading human monoclonal antibody biopharmaceutical company, announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse® platform. Kymab will have the development and commercialization rights to these bispecifics in all geographical regions outside of China, and, under the terms of the cross license agreement, EpimAb will have the rights for the China market.
On June 6, 2016 EpimAb and Innovent Biologics, one of the leading biopharmaceutical companies in China, announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent gained access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China.